Ivermectin,
does it really help with Reduced hospitalization, death, and recovery time in early COVID-19?
research showsIvermectin is rated F for improving hospitalization, death, or recovery in early COVID-19. In TOGETHER, comparing 679 ivermectin recipients with 679 placebo recipients, hospitalization or prolonged emergency observation was not significantly reduced: RR 0.90 with a 95% Bayesian credible interval of 0.70 to 1.16, and secondary outcomes showed no benefit. The 1,591-participant ACTIV-6 trial also found no significant improvement in sustained recovery or hospitalization and death. The 2022 Cochrane update synthesized no benefit for outpatient mortality, worsening, or symptom resolution. Multiple large trials and systematic evidence repeatedly refute the claim, supporting F with 6 points. Efficacy against parasitic infections is a separate indication and must not be confused with COVID-19 outcomes.
ads claimIn-vitro viral inhibition, long antiparasitic experience, and small early trials are expanded into prevention of COVID-19 hospitalization and death. Efficacy for a parasitic indication and efficacy for COVID-19 are different questions.
Useful facts when choosing a product
- Ivermectin is a prescription antiparasitic used for selected infections such as strongyloidiasis and filarial disease; that is separate from COVID-19 efficacy.
- Veterinary formulations must not be used for COVID-19 because their doses and excipients differ from human products and can cause serious poisoning.
- Common adverse effects include dizziness, nausea, diarrhea, and rash, while overdose can cause confusion, ataxia, hypotension, seizures, and other neurotoxicity.
- Drug interactions, including with warfarin, are possible, and liver disease, high or repeated dosing, and concurrent parasitic infection require individualized medical assessment.
What the research actually shows
The TOGETHER trial compared 679 ivermectin recipients with 679 placebo recipients and found primary events in 14.7% versus 16.3%, RR 0.90. ACTIV-6 compared 817 participants receiving ivermectin 400 micrograms per kilogram for three days with 774 receiving placebo and reported a sustained-recovery HR of 1.07 with a 95% Bayesian credible interval of 0.96 to 1.17, with hospitalization or death in 10 versus 9 participants. The 2022 Cochrane review found outpatient mortality RR 0.77, 95% CI 0.47 to 1.25, across six trials and 2,860 participants, with no meaningful benefit across major outcomes. In-vitro antiviral signals required exposures that do not establish clinical efficacy at safe human dosing.
Why this is classified as F (6)
Large randomized TOGETHER and ACTIV-6 trials found no hospitalization, mortality, or sustained-recovery benefit, and the updated Cochrane review confirmed the pattern. Early positive signals and in-vitro findings cannot overcome higher-quality repeated refutation, supporting F with 6 points. Antiparasitic efficacy and neurologic or overdose toxicity remain separate issues.
Counterpoint. Efficacy against parasitic infection does not imply efficacy against COVID-19. Early COVID-19 treatment should use options validated for the patient's current variant-era risk and contraindications in consultation with a clinician.
Rejudgment record. New verdict — Applied F for repeated refutation because large randomized TOGETHER and ACTIV-6 trials and the 2022 Cochrane update consistently found no benefit for hospitalization, death, or recovery in early COVID-19
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced hospitalization and death in early COVID-19 | F | TOGETHER, ACTIV-6, and synthesized evidence repeatedly found no benefit. |
| Shortened recovery time in early COVID-19 | F | ACTIV-6 did not improve sustained recovery, and total evidence does not support a clinically meaningful shortening. |
| Extrapolation of in-vitro SARS-CoV-2 inhibition to human treatment efficacy | D | In-vitro concentrations did not establish clinical efficacy, and large human trials were null. |
| Treatment of validated parasitic indications such as strongyloidiasis | B | This is a validated separate indication, and its efficacy was neither mixed into nor counted as rescue evidence for the COVID-19 score. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Reis G et al. TOGETHER 2022 | Adaptive randomized double-blind placebo-controlled platform trial | 679 | FastGrants and the Rainwater Charitable Foundation | Hospital admission or at least six hours of emergency observation for COVID-19 progression | 14.7% versus 16.3%; RR 0.90 (95% Bayesian credible interval 0.70 to 1.16), with no significant secondary benefit. | Pivotal large direct null evidence |
| Naggie S et al. ACTIV-6 2022 | Decentralized randomized double-blind placebo-controlled platform trial | 774 | Supported by the United States NIH | Time to sustained recovery, hospitalization, and death | Recovery HR 1.07 (95% Bayesian credible interval 0.96 to 1.17); hospitalization or death in 10 versus 9 participants. | Independent large direct null evidence |
| Popp M et al. Cochrane 2022 update | Systematic review of randomized trials | 2,860 | Cochrane review with public or institutional author support | Mortality, clinical worsening, symptom resolution, and viral clearance | Evidence strengthened that ivermectin provided no beneficial effect on major outcomes in outpatient COVID-19. | Synthesis of repeated refutation |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Ivermectin x reduced hospitalization, death, and recovery time in early COVID-19 — Evidence Grade F·6. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/ivermectin-early-covid19-hospitalization-mortality-recovery/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.